New Phase Ltd. is introducing a groundbreaking innovation for the treatment of advanced metastatic solid tumors. Known as The Sarah Nanotechnology System, this medical device is designed to deliver controlled thermal energy directly to malignant cells, offering a potential new avenue for addressing stage 4 cancers. This development represents a significant step forward in the field of medical devices and oncology therapies.
The clinical trial for this device is not yet recruiting and aims to assess its performance and safety in delivering thermal destruction of malignant cells for affected patients.
Published: November 4, 2025
In this article:
- What is The Sarah Nanotechnology System?
- How does the thermal destruction mechanism work?
- What are the trial details?
- Frequently Asked Questions
- Key takeaways
- Disclaimer
- For more details
What is The Sarah Nanotechnology System?
The Sarah Nanotechnology System is a medical device developed by New Phase Ltd. It is specifically intended for the treatment of stage 4 cancer patients with advanced metastatic solid tumors.
The device uses hyperthermia—a treatment method that involves applying thermal energy to tumor cells. The goal is thermal destruction, which could reduce or eliminate malignant growth without affecting surrounding healthy tissues.
How does the thermal destruction mechanism work?
Hyperthermia treatment targets cancer cells using precisely delivered heat energy. Malignant cells are often more sensitive to elevated temperatures compared to healthy cells, making hyperthermia a promising therapeutic approach. The Sarah Nanotechnology System aims to ensure targeted thermal effects with minimal damage to adjacent structures.
This approach aligns with regulatory guidance for medical device performance assessments, particularly safety measures to minimize risks associated with thermal injuries.
What are the trial details?
The upcoming clinical trial remains in the early planning phase, and recruitment for participants has not yet started as of November 2025. Sponsored by New Phase Ltd., the trial will focus on evaluating the device’s efficacy and safety for patients suffering from metastatic solid tumors.
Enrollment timelines and study protocols have yet to be fully outlined on ClinicalTrials.gov, where updates will be provided. Interested clinicians and regulatory teams should monitor the trial link for further announcements.
Frequently Asked Questions
- What conditions does this device target?
The Sarah Nanotechnology System is developed for advanced metastatic solid tumors, classified as stage 4 cancer. - Is the clinical trial currently recruiting?
No, recruitment for the trial has not yet started as of November 2025. - Who is sponsoring the trial?
The trial is sponsored by New Phase Ltd. - How can I stay updated?
Updates about the trial will be available on ClinicalTrials.gov. The trial listing is accessible here.
Key takeaways
The introduction of The Sarah Nanotechnology System sets the stage for exploring new therapeutic options for stage 4 cancer affected by metastatic tumors. As the clinical trial progresses, the focus will remain on evaluating the device’s potential to deliver safe and effective hyperthermia treatment. Stakeholders in oncology, medical devices, and regulatory affairs should closely follow updates.
Disclaimer
This article is intended for informational purposes only and does not constitute medical, clinical, or legal advice. Users should consult appropriate professionals before acting on any information provided herein.
For more details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07224464?term=medical+device